结直肠癌腹膜转移根治性治疗后腹膜及腹膜外复发的生存预期
本研究基于前瞻性数据库分析结直肠癌腹膜转移患者接受完全肿瘤细胞减灭术(CRS)联合腹腔热灌注化疗(HIPEC)后复发的模式及不同治疗方式的结局。190例复发患者中,孤立腹膜复发31%、孤立远处复发35%、多部位复发34%;接受根治性意向治疗者3年和5年总生存分别为77%和46%,未接受者仅14%和4.7%。
要点
- CRS+HIPEC后复发以孤立腹膜(31%)和孤立远处(35%)为主,多部位占34%。
- 根治性意向治疗率:孤立腹膜48%、孤立远处49%、多部位22%(p=0.002)。
- 根治性意向治疗者中位生存59.7个月,未接受者18.3个月(log-rank p<0.0001)。
核心结论
- 对CRS+HIPEC后复发的结直肠癌腹膜转移患者,选定的患者可接受根治性意向的再次治疗,并与生存延长相关。
研究设计与样本
- 采用Kaplan-Meier估计和多因素Cox回归模型分析再次根治性意向治疗的影响。
主要发现
- 复发模式:孤立腹膜复发31%、孤立远处复发35%、多部位复发34%。
- 根治性意向治疗率分别为孤立腹膜复发48%、孤立远处复发49%、多部位复发22%(p=0.002)。
- 自复发诊断起,根治性意向治疗者3年和5年总生存分别为77%和46%,非根治性治疗者为14%和4.7%,中位生存分别为59.7个月和18.3个月(log-rank p<0.0001)。
- 多因素回归显示初始腹膜转移范围(HR 2.25;p<0.0001)、再次根治性意向治疗(HR 0.22;p<0.0001)和无病间期(HR 1.77;p=0.01)为生存延长的独立预测因素。
关键数值与推荐
- 复发后接受根治性意向治疗者3年总生存77%、5年总生存46%,中位生存59.7个月。
- 复发后未接受根治性治疗者3年总生存14%、5年总生存4.7%,中位生存18.3个月。
- 初始腹膜转移范围HR 2.25(p<0.0001)、再次根治性意向治疗HR 0.22(p<0.0001)、无病间期HR 1.77(p=0.01)。
临床怎么用
- 对CRS+HIPEC后复发的结直肠癌腹膜转移患者,应评估再次根治性意向治疗的可行性。
- 孤立腹膜或孤立远处复发者根治性意向治疗率较高(约48%-49%),多部位复发者较低(22%)。
- 初始腹膜转移范围广和无病间期短者预后较差,决策时需结合这些因素综合判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Over the last 20 years, complete cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) dramatically increased the survival of patients with colorectal peritoneal metastases (CRPM). However, despite better knowledge of the disease, around 70% of patients relapse after CRS with HIPEC. This study was designed to analyse the pattern of recurrence and the outcomes of different treatment modalities. METHODS: Patients relapsing after CRS plus HIPEC for CRPM were selected from a prospective database. The impact of iterative curative-intent treatments was analysed using Kaplan-Meier estimates and multivariate Cox regression models. RESULTS: Between April 1993 and December 2014, 190 of 274 (69%) patients previously treated by CRS plus HIPEC developed relapse, as an isolated peritoneal recurrence (31%), isolated distant recurrence (35%), or multisite recurrence (34%). The curative-intent treatment rate was 48% for isolated peritoneal recurrences, 49% for isolated distant recurrences and 22% for multisite recurrences (p = 0.002). From the diagnosis of relapse, 3- and 5-year overall survival were 77% and 46% after curative-intent treatment and 14% and 4.7% after non-curative treatment, with median survival of 59.7 and 18.3 months (log-rank p < 0.0001), respectively. Regression analysis identified the initial extent of CRPM (hazard ratio [HR]: 2.25; p < 0.0001), iterative curative-intent treatment (HR: 0.22; p < 0.0001) and disease-free interval (HR: 1.77; p = 0.01) as independent predictors of prolonged survival. CONCLUSIONS: Iterative curative-intent treatment can be performed in up to 40% of patients with relapse after CRS and HIPEC for CRPM, and is associated with prolonged survival in selected patients.
引用
- Gelli M, Huguenin JFL, de Baere T, et al. Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect? Eur J Cancer. 2018. PMID: 30014885. doi:10.1016/j.ejca.2018.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。